CompletedNot Applicable

Benign Migratory Glossitis Associated With Antiangiogenic Drugs

Brazil8 participantsStarted 2017-07-16

Plain-language summary

Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient's charts which underwent antiangiogenic targeted drugs Exclusion Criteria: * chemoterapy without angiogenesis inhibitors

What they're measuring

Benign migratory glossitis

Timeframe: From enrollment to the end of study at 7 years

Trial details

NCT IDNCT06988865

SponsorInstituto do Cancer do Estado de São Paulo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01-10

View on ClinicalTrials.gov More Cancer trials